Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial

The paper gives the results of the phase III clinical trial of adalimumab (ADA) biosimilar, (BCD-057) (BIOCAD, Russia), which demonstrate the clinical equivalence of the biosimilar to the ADA innovator Humira® in patients with moderate and severe psoriasis.Objective. The BCD-057-2/CALYPSO phase III...

詳細記述

書誌詳細
主要な著者: Т. V. Korotaeva, A. V. Samtsov, A. L. Bakulev, M. M. Kokhan, I. K. Minullin, O. A. Vylegzhanina, V. V. Dubensky, B. V. Khalilov, A. A. Khotko, O. S. Zykova, I. V. Chumachenko, A. M. Lukyanov, A. V. Artemyeva, S. I. Derbin, E. Yu. Stukalina, E. V. Chernyaeva, R. A. Ivanov
フォーマット: 論文
言語:Russian
出版事項: IMA-PRESS LLC 2018-12-01
シリーズ:Современная ревматология
主題:
adalimumab
biosimilar
bcd-057
psoriasis
オンライン･アクセス:https://mrj.ima-press.net/mrj/article/view/865

インターネット

https://mrj.ima-press.net/mrj/article/view/865

類似資料